HSD11B1 and Cushing syndrome due to macronodular adrenal hyperplasia: Such findings have prompted research aimed at inhibiting HSD11B1 as a possible pharmacological target for the prevention of adverse metabolic profiles associated with glucocorticoid excess, such as Cushing syndrome, metabolic syndrome and obesity (Pereira et al., 2012; Morgan et al., 2014).